Research programme: cell therapies - Astellas Institute for Regenerative Medicine

Drug Profile

Research programme: cell therapies - Astellas Institute for Regenerative Medicine

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocata Therapeutics
  • Developer Astellas Institute for Regenerative Medicine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Corneal disorders
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 29 Dec 2015 Early research in Corneal disorders in USA (unspecified route)
  • 24 Aug 2015 Ocata Therapeutics receives SBIR grant from the National Institute of Allergy and Infectious Diseases for hemangio-derived mesenchymal cell development in systemic lupus erythematosus and lupus nephritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top